N/A N=82 VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Hypertension
Primary: Mean Percentages of Events After Index Visit to Primary Care by Patient — 25.4; 30.6; 59.6; 55.2 mean percentage of events — p=>0.1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Phase 2 N=50 An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations — 0.10; -0.12; -0.05; -0.83 percent HbA1c — p=0.0475
N/A N=202 SILS™ Port Laparoscopic Cholecystectomy Post Market Study
Gallbladder Disease
Primary: Feasibility and Safety of SILS™ Port Cholecystectomy Versus 4PLC — 53; 29; 14; 5 Participants
Phase 1 N=36 Phase 1 Safety and Immunogenicity of Meningococcal Vaccine
Meningococcal Infection, Group B
Primary: Bactericidal Absolute Values After Group B Meningococcal 8570 HOPS-G NOMV Vaccine Injections — 2.1; 3.0; 3.0; 2.4 titers
Phase 3 N=195 Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Metastatic Breast Cancer
Primary: Time to Progression — 8.68; 6.84 months — p=0.1224
Phase 3 N=112 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
Allergy · Asthma · Rhinitis
Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml
N/A N=213 Engagement of Patients With Advanced Cancer
End of Life · Advanced Cancer · Lung Neoplasm
Primary: Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled…
N/A N=79 Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis
Hip Osteoarthritis · Knee Osteoarthritis
Primary: Hip and Knee Decision Quality Instruments Knowledge Subscale Scores — 55.2; 48.8 units on a scale — p=<0.05
N/A N=99 A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
Immunologic Tests
Primary: Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell…
N/A N=50 Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores
Postoperative Pain
Primary: Numeric Pain Rating Scale — 2.0; 2.7; 2.9 units on a scale
N/A N=29 Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures
Convulsion, Non-Epileptic
Primary: Completion Rate of Auricular Acupuncture in Patients With NES — 15 Participants
Phase 2 N=267 Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
HIV Prevention · HIV Infections
Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05
N/A N=94 Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty
Total Knee Arthroplasty
Primary: Quadriceps Muscle Strength — 7.3; 2.2 kilogram-force
N/A N=882 Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
STEMI
Primary: Percentage of Sites With Reduction in Door to Balloon Time — 83; 50 percentage of sites with improved D2B